## **APOLLO HOSPITALS ENTERPRISE LIMITED**



CIN: L85110TN1979PLC008035

August 11, 2023

The Secretary, Bombay Stock Exchange Ltd (BSE) Phiroze Jheejheebhoy Towers, Dalal Street, Mumbai – 400 001. Scrip Code – 508869 ISIN INE437A01024

The Secretary, National Stock Exchange, Exchange Plaza, 5th Floor Plot No.C/1, 'G' Block Bandra – Kurla Complex Bandra (E) Mumbai – 400 051. Scrip Code– APOLLOHOSP ISIN INE437A01024 The Manager The National Stock Exchange, Wholesale Debt Market Exchange Plaza, 5th Floor Plot No.C/1, 'G' Block Bandra – Kurla Complex Bandra (E) Mumbai – 400 051. **ISIN INE437A08052** 

Dear Sir,

Subject: Disclosure under Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

In compliance with Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose herewith the Investor Presentation on the Financial Results of the Company for quarter ended June 30. 2023.

The presentation to be made to the Investors is enclosed and the same is also being uploaded on the Company's website <u>www.apollohospitals.com</u>.

Kindly note of the same.

Thanking You,

Yours faithfully, For APOLLO HOSPITALS ENTERPRISE LIMITED

S.M. KRISHNAN Sr. VICE PRESIDENT – FINANCE AND COMPANY SECRETARY

IS/ISO 9001 : 2000

**Regd. Office :** 19, Bishop Gardens, Raja Annamalaipuram, Chennai - 600 028. **General Office :** "Ali Towers" III Floor, #55, Greams Road, Chennai - 600 006. Tel: 044 - 28290956 / 3896 / 6681Telefax: 044 - 2829 0956Email: investor.relations@apollohospitals.comWebsite: www.apollohospitals.com



# APOLLO HOSPITALS ENTERPRISE LIMITED

**Earnings Update Q1 FY24** 





# **HIGHLIGHTS**

**Key Highlights** 







**Financials** 






Diagnostics & Retail Health



Digital Health & Pharmacy Distribution **06** Annexure

## **Highlights Q1FY24 : Operational**








- Apollo Hospitals leads India's Solid Multi-Organ Transplantation with over 23,000 transplants, establishes global leadership.
- Apollo expands its dedicated Robotic Colorectal Surgery Programme across 6 cities Chennai, Hyderabad,
   Bangalore, Delhi, Mumbai and Vishakhapatnam. Apollo's collective robotic colorectal surgery experience has now surpassed over 1000 procedures, maximum till date in the country.
- Commemorating World Thalassemia Month, Apollo Cancer Centre, Chennai, in association with the Tamil Nadu
   Government, celebrated the milestone of successfully treating the highest number of Thalassemia affected children
   under the Tamil Nadu CM's Comprehensive Health Insurance Scheme
- Apollo Hospitals, Navi Mumbai celebrates a lifesaving milestone of 40 Bone Marrow Transplants in four years.
- Apollo Proton Cancer Centre has launched the first and largest Helical Tomotherapy program in Tamil Nadu.

### **Clinical Updates**

## **Highlights Q1FY24 : Financials**









# **Financials**

## Consolidated

## Consolidated Financials Q1 FY24

+

₹ Mio		Healthcare Services	Diagnostics & Retail Health	Digital Health & Pharmacy Distribution	Consol
	Total Revenues	22,937	3,187	18,054	44,178
	EBITDA (Pre 24 7 Cost)	5,423	233	1,473	7,129
	margin (%)	23.6%	7.3%	8.2%	16.1%
	24/7 Operating Cost			-1,747	-1,747
	ESOP(Non Cash expense)			-292	-292
Q1 FY 24	EBITDA	5,423	233	-566	5,090
Q17124	margin (%)	23.6%	7.3%	-	11.5%
	EBIT	4,211	-103	-687	3,421
	margin (%)	18.4%	-	-	7.7%
	PBT	3,729	-205	-825	2,700
	margin (%)	16.3%	-	-	6.1%
	PAT (Reported)	2,639	-147	-826	1,666
	Total Revenues	20,234	2,930	14,792	37,956
	EBITDA (Pre 24 7 Cost)	4,844	294	1,181	6,319
	margin (%)	23.9%	10.0%	8.0%	16.6%
	24/7 Operating Cost			-1,412	-1,412
	ESOP(Non Cash expense)			0	0
	EBITDA	4,844	294	-230	4,907
Q1 FY 23	margin (%)	23.9%	10.0%	-	12.9%
	EBIT	3,706	60	-336	3,430
	margin (%)	18.3%	2.0%	-	9.0%
	PBT	3,132	-89	-500	2,543
	margin (%)	15.5%	-	-	6.7%
	PAT (Normalized for exceptional charge / write back) <sup>1</sup>	2,224	-59	-460	1,705
YOY Growth					
Revenue		13%	9%	22%	16%
EBITDA (Pre 24 7	Cost)	12%	-21%	25%	13%

	HCS	Health Co	AHLL
Gross Debt	20,803	5,415	2,683
Cash & Cash Equivalents	12,285	353	1,026
Net Debt	8,518	5,062	1,657

Includes investments in liquid funds and FDs of ₹ 8,859 mio

**Q1FY23** <sup>1</sup> :**Consol Reported PAT of ₹ 3,171mio** after accounting for one-off Deferred Tax reversal on migration to lower tax regime of ₹1,466 mio;





# **Healthcare Services**

## Hospitals

**Consolidated Healthcare Services Performance Q1FY24** 



₹ Mio		Healthcare Serv Group (Mature)	Healthcare Serv Group (New & Others)	Healthcare Serv Group
	No of Hospitals	29	14	43
	Operating beds	5418	2380	7798
	Occupancy	63%	60%	62%
	Revenue	15,845	7,092	22,937
	EBITDA	4,242	1,181	5,423
Q1 FY 24	margin (%)	26.8%	<b>16.7%</b>	23.6%
	EBIT	3,504	706	4,210
	margin (%)	22.1%	10.0%	18.4%
	PBT			3,729
	PAT			2,639
	Margin			11.5%
	No of Hospitals	29	15	44
	Operating beds	5443	2421	7864
	Occupancy	62%	55%	60%
	Revenue	14,466	5,768	20,234
	EBITDA	3,822	1,022	4,844
Q1 FY 23	margin (%)	26.4%	17.7%	23.9%
	EBIT	3,157	549	3,705
	margin (%)	21.8%	9.5%	18.3%
	PBT			3,132
	PAT			2,224
	margin (%)			11.0%
YOY Growth				
Revenue		10%	23%	13%
BITDA		11%	16%	12%

HCS Revenue grew by 13% (Volume growth 6%, price and case mix of 7%) and EBITDA grew by 12% in Q1FY24.

Self pay and insurance revenue grew over 20% vs. Q1FY23

Overall Surgical mix at 68% of IP Revenues – higher growth in Q1 aided by CONGO specialties.

CONGO - Cardiac, Onco, Neuro, Nephro, Gastro and Ortho contributes to 63% of Hospital Revenues – and continue to be our focus areas for growth

ARPOB grew by **11%** to **₹ 57,760** in Q1FY24.



\*CWIP of ₹ 6,355 mio towards new projects under development

## Region wise Operational Parameters



		Total <sup>(6)</sup>		Tar	Tamilnadu Region (Chennai & others) <sup>(1)</sup>		AP, Telengana Region (Hyderabad		
				(Che			& others) (2)		)
Particulars	Q1 FY 23	Q1 FY 24	yoy (%)	Q1 FY 23	Q1 FY 24	yoy (%)	Q1 FY 23	Q1 FY 24	yoy (%)
No. of Operating beds	7,864	7,798		2,156	2,088		1,297	1,270	
Inpatient volume	126,511	133,846	5.8%	33,952	35,246	3.8%	17,675	18,529	4.8%
Outpatient volume <sup>(7)</sup>	462,633	458,694	-0.9%	146,628	135,311	-7.7%	43,563	48,383	11.1%
Inpatient ALOS (days)	3.38	3.27		3.24	3.15		3.53	3.38	
Bed Occupancy Rate (%)	60%	62%		56%	58%		53%	54%	
Inpatient revenue (₹ mio)	NA	NA		5,333	6,100	14.4%	2,642	2,933	11.0%
Outpatient revenue (₹ mio)	NA	NA		1.811	1.979	9.3%	510	596	16.7%
ARPOB (₹ /day) <sup>(8)</sup>	51,999	57,760	11.1%	64,850	72,884	12.4%	50,528	56,279	11.4%
Total Net Revenue (₹ mio) <sup>(6)</sup>	NA	NA		7,144	8,079	13.1%	3,152	3,529	12.0%

	Karnataka Region (Bangalore & others) <sup>(3)</sup>				Others (4)		Significant Subs/JVs/associates		
Particulars	Q1 FY 23	Q1 FY 24	yoy (%)	Q1 FY 23	Q1 FY 24	yoy (%)	Q1 FY 23	Q1 FY 24	yoy (%)
No. of Operating beds	761	756		1,132	1,153		2,518	2,531	
Inpatient volume	14,163	15,093	6.6%	18,697	18,896	1.1%	42,024	46,082	9.7%
Outpatient volume <sup>(7)</sup>	45,296	47,663	5.2%	51,498	43,128	-16.3%	175,648	184,209	4.9%
Inpatient ALOS (days)	2.97	2.80		3.45	3.29		3.52	3.48	
Bed Occupancy Rate (%)	61%	61%		63%	59%		65%	70%	
Inpatient revenue (₹ mio)	1,873	2,260	20.7%	1,899	2,161	13.8%	5,668	6,878	21.4%
Outpatient revenue (₹ mio)	367	413	12.4%	386	385	-0.2%	1,427	1,668	16.8%
ARPOB (₹ /day) <sup>(8)</sup>	53,178	63,187	18.8%	35,386	41,010	15.9%	47,924	53,360	11.3%
Total Net Revenue (₹ mio) <sup>(6)</sup>	2,241	2,673	19.3%	2,285	2,546	11.4%	7,095	8,546	20.5%

Q1FY24 ARPOB in Metro cities at ₹ 69,092 and Non Metro cities is at ₹ 40,612. Blended ARPOB ₹ 57,760

#### Notes:

(1) Tamilnadu region includes Chennai hospitals, Madurai, Karur, Karaikudi, Trichy & Nellore.

(2) AP, Telangana Region includes Hyderabad, Karimnagar, Vizag old, Vizag new & Kakinada.

(3) Karnataka region includes Bangalore, Mysore, Jayanagar & Malleswaram.

(4) Others include Bhubaneswar, Bilaspur, Nashik & Navi Mumbai.

(5) Significant Hospital JVs/Subs/Associates are – Ahmedabad, Kolkata, Delhi, Indore, Assam & Lucknow (full revenues shown in table above).

(6) Revenues under the head "Total" have not been provided as Consolidated actual results will differ from total due to proportionate consolidation.

(7) Outpatient volume represents New Registrations only.

(8) Revenues under Ind AS have been grossed up for Fixed fee Doctors & considered separately as operating cost. This was earlier being netted off from Revenues under Indian GAAP. ARPOB excludes Vaccination Revenue





## Executive Summary



- Selective network additions being planned in key metro markets (viz. Bangalore, Chennai, Delhi NCR, Hyderabad)
- Focus on creating distinguished end to end out patient experience
- Corporate empanelment via customized portals for better utilization of employee benefits
- · Focus on strengthening omni-channel service offerings for delivering continuum of care
- Diagnostics business added 260+ collection centres taking the overall collection network to 1910+ centres spread across ~260 cities serving 13,000+ customers daily.
- Aim to reach 3,000+ collection centers by end of year
- · Focus on building wellness as a significant segment and higher contribution from Specialty/super specialty tests
- Cradle: Expansion in key markets across select metros to consolidate market share; 1 new centre launched in April 2023, 2-3 units to be commissioned by Q3 FY24; Focus on building deeper capabilities for advanced pediatrics and comprehensive women's health
- Spectra: Focus on building specialty focused niche service offerings for micro-market leadership (viz. Urology, Bariatrics, Audiology etc.) Aggressive ramp up of the digital customer acquisition model
- Fertility; Unit economics stabilizing with centres establishing firm foothold in primary markets; Focus on improving direct customer engagement via digital and offline activities

## **Primary Care**

## Diagnostics

## Specialty Care

## Financial Performance Q1FY24



Q1 FY24	Clinics	Diagnostics	Sugar	Dental	Dialysis	Cradles (IP)	IVF	Spectra (IP)
Network	350	2,012	65	133	119	10	17	11
Footfalls/Day*	2,258	14,106	472	223	1,850	46	39	72
Gross ARPP (Rs.)*	2,060	744	3,035	6,208	1,618	106,989	37,047	105,941

AHLL Core Revenues (excluding Covid Vaccination, Covid Testing and Isolation Centre Revenues which were one-off revenues during Q1FY23) grew by 19% YoY in Q1 FY 24.

5 Q1 FY23	Diagnostics	Primary Care	Specialty Care	Corporate	Intra Group	AHLL (Consol)
Q1 FY24	1075	847	1430	0	-164	3,187
Q1 FY23	815	851	1397	0	-133	2,930
Q1 vs Q1	32%	0%	2%			9%
Q1 FY24	75	103	206	-152	0	233
Q1 FY23	39	135	215	-96	0	294
		-			-	
Q1 FY24	7%	12%	14%	-	0%	7%
Q1 FY23	5%	16%	15%	-	0%	<b>10%</b>
Q1 FY24	44	37	-29	-155	0	-103
Q1 FY23	10	71	77	-99	0	60
Q1 FY24	36	7	-88	-169	0	-214
Q1 FY23	2	39	-20	-108	0	-87
	Q1 FY24 Q1 FY23 Q1 vs Q1 Q1 FY24 Q1 FY23 Q1 FY23 Q1 FY23 Q1 FY24 Q1 FY23 Q1 FY24 Q1 FY24	Q1 FY24       1075         Q1 FY23       815         Q1 vs Q1       32%         Q1 FY24       75         Q1 FY23       39         Q1 FY23       5%         Q1 FY24       44         Q1 FY23       10         Q1 FY24       36	Q1 FY24         1075         847           Q1 FY23         815         851           Q1 vs Q1         32%         0%           Q1 FY24         75         103           Q1 FY23         39         135           Q1 FY24         7%         12%           Q1 FY23         5%         16%           Q1 FY24         10         71           Q1 FY24         36         7	Q1 FY24       1075       847       1430         Q1 FY23       815       851       1397         Q1 vs Q1       32%       0%       2%         Q1 FY24       75       103       206         Q1 FY23       39       135       215         Q1 FY24       7%       12%       14%         Q1 FY23       5%       16%       15%         Q1 FY24       44       37       -29         Q1 FY23       10       71       77         Q1 FY24       36       7       -88	Q1 FY24         1075         847         1430         0           Q1 FY23         815         851         1397         0           Q1 vs Q1         32%         0%         2%           Q1 FY24         75         103         206         -152           Q1 FY23         39         135         215         -96           Q1 FY23         39         135         215         -96           Q1 FY24         7%         12%         14%         -           Q1 FY23         5%         16%         15%         -           Q1 FY24         7%         12%         14%         -           Q1 FY23         5%         16%         15%         -           Q1 FY23         10         71         77         -99           Q1 FY24         36         7         -88         -169	Q1 FY24         1075         847         1430         0         -164           Q1 FY23         815         851         1397         0         -133           Q1 vs Q1         32%         0%         2%         0         -133           Q1 FY24         75         103         206         -152         0           Q1 FY23         39         135         215         -96         0           Q1 FY23         39         135         215         -96         0           Q1 FY23         5%         16%         15%         -         0%           Q1 FY23         5%         16%         15%         -         0%           Q1 FY24         44         37         -29         -155         0           Q1 FY23         10         71         77         -99         0

Non-Covid Diagnostics revenue (excluding Covid Testing) **grew by 48% YoY** in Q1 FY24.

Core Revenues of Primary Care grew by 23%


\* Footfalls and ARPP for diagnostics represent outpatient / external business and for Cradle and Spectra it represents Inpatient volumes. Primary care includes Clinics, Sugar, Dental and Dialysis segments. Specialty care includes Cradles, IVF and Spectra.

## **Diagnostics : Key Parameters**






#### Gross Revenue (INR Mn)<sup>1</sup>



#### Avg. Footfalls per day & Avg. gross realization per patient (INR)<sup>2</sup>



#### 1. Covid Revenues include RTPCR and Antibody test revenues; exclude Covid Allied tests

2. EBITDA post IND AS 116;

\* Footfalls and ARPP for diagnostics represent outpatient / external business

#### Network Growth – Collection Centers

EBITDA (INR Mn)<sup>2</sup>




## **Operational footprint** (as of Jun 30, 2023)



# Digital Health & Pharmacy Distribution Apollo Health Co

## India's Largest Omni-Channel Healthcare





## Health Co Financials Q1 FY24

-336

-500

-460



₹ Mio		Offline Pharmacy Distribution	Online Pharmacy Distribution & Apollo 247	Total Health Co
	Total Revenues	16,001	2,053	18,054
	EBITDA*	1,250	223	1,473
	margin (%)	7.81%	10.88%	8.16%
	24 7 Operating Cost		-1,747	-1,747
04 57 24	ESOP Non Cash Charge		-292	-292
Q1 FY 24	EBITDA	1,250	-1,816	-566
	margin (%)	7.8%	-	-
	EBIT			-687
	PBT			-825
	PAT(Reported)			-826
	-			
	Total Revenues	13,586	1,206	14,792
	EBITDA*	1,102	79	1,181
	margin (%)	8.1%	6.6%	8.0%
	24 7 Operating Cost		-1,412	-1,412
Q1 FY 23	ESOP Non Cash Charge		0	0
QIFT 25	EBITDA	1,102	-1,333	-230
	margin (%)	8.1%	-	-

PAT(Reported)
\* Excluding 24/7 operating Cost and ESOP Non-Cash Charge

#### Healthco :

- o 22% growth in revenue in Q1' FY24 vs Q1' FY23
- 20% reduction in losses in Q1' FY24 (Rs 566 Mn) vs Q4' FY23 (Rs 721 Mn) majorly on account of reduction in digital operating cost.
- Expect to break-even in Q4'FY24

EBIT

PBT

#### **Omnichannel Pharmacy:**

- Omnichannel Pharmacy Business revenue of Rs 22,464 Mn in Q1' FY24 compared to a revenue of Rs 18,081 Mn in Q1' FY23 (growth of 24%) despite muted growth in FMCG and Pharma Sector in Q1'FY24.
  - Online grew 59% in Q1 FY24 vs Q1 FY23
  - Offline grew 21% in Q1 FY24 vs Q1 FY'23
  - Private label sales/ generic sales at 16%.

#### On track to achieve Rs 10,000 cr of revenues with 6% EBITDA in current fiscal year.

#### Digital Operational Metrics :

Platform GMV : Rs 6,227 Mn in Q1' FY24, growth of 189% over Q1' FY23 and 5% growth over Q4' FY23.

Improvement in quantitative parameters in Q1' FY24 vs Q1' FY23;

- Pharma AOV grew by 11% (Rs 935 vs Rs 845 a year back)
- Transacting user base grew by 31% (11.4 lakh vs 8.7 lakh, a year back)

#### Offline segment :

Improvement in quantitative parameters (5,573 stores)

- 22% YoY growth in transactions (6.2cr Vs 5.1cr year back).
- Serving 8 lac customers per day.





## **Basis of Consolidation**



AHEL Ownership

> 100.00% 68.84%

> 100.00% 51.00% 90.00% 50.00% 69.95% 54.63% 100.00%

100.00% 100.00% 100.00% 100.00% 100.00% 89.69% 80.87% 70.00% 51.00% 100.00% 60.00% 22.03% 49.00% 50.00% 37.75% 50.00%

AHEL Standalone Hospitals (100% Ownership)	Location	Subsidiaries	Location	Description
Chennai Main	Chennai	Material Subs		
ACI - Chennai	Chennai	Apollo Health Co limited	India	Digital Omni-Channel Healthcare se
Tondiarpet - Chennai	Chennai	Apollo Health and Lifestyle Ltd.	India	Clinics, Diagnostics and Daycare
FirstMed - Chennai	Chennai	Apollo Multispeciality Hospitals Ltd.	Kolkata	Hospital
Apollo Children's Hospital	Chennai	Apollo Medics	Lucknow	Hospital
Apollo Specialty, Vanagaram	Chennai	Imperial Hospital and Research Centre Ltd.	Bangalore	Hospital
		Apollo Hospitals International Ltd.	Ahmedabad	Hospital
ASH Perungudi	Chennai	Assam Hospitals Ltd	Assam	Hospital
Women & Child, Shafee Mohammed Road	Chennai	Apollo Rajshree Hospital	Indore	Hospital
Apollo Proton & Cancer care	Chennai	Samudra Healthcare Enterprises Ltd.	Kakinada	Hospital
Madurai	Madurai	Other Subs		
Karur	Karur	Apollo Hospitals (UK) Ltd	UK	UK Hold Co
		AB Medical Centres Limited	Chennai	Infrastructure
Karaikudi	Karaikudi	Total Health	India	CSR
Trichy	Trichy	Apollo Hospitals Singapore.PTE Limited	Singapore	Singapore Hold Co
Nellore	Nellore	Future Parking Pvt Ltd	Chennai	Infrastructure
Hyderabad	Hyderabad	Apollo Home Health care Ltd	India	Paramedical Services
Bilaspur	Bilaspur	Pinakini Hospitals Ltd.	Nellore	Hospital
Mysore		Sapien Bioscienses Pvt Ltd	Hyderabad	Biobanking tissues
· ·	Mysore	Apollo Lavasa Health Corporation Ltd	Maharashtra	Hospital
Vizag (old & new)	Vizag	Apollo Hospitals North Limited	Gurgaon	Hospital
Karim Nagar	Karim Nagar	Kerala First Health Services Private Limited	Kerala	Hospital
Bhubaneswar	Bhubaneswar	Associates	Location	Description
Jayanagar	Bangalore	Indraprastha Medical Corporation Ltd.	Delhi, Noida	Hospital
Nashik	Nashik	Family Health Plan Ltd.	India	TPA, Health Insurance
Malleswaram		ApoKos Rehab Pvt Ltd	Hyderabad	Rehab Centre
	Bangalore	Stemcyte India Therapautics Pvt Ltd	India	Stemcell Banking
Navi Mumbai	Mumbai	Apollo Gleneagles PET-CT Pvt Ltd	Hyderabad	Diagnostics



# Thank you !